← Back to Clinical Trials
Recruiting NCT07769008

NCT07769008 CCTA-Based vs CAG-Based CABG: A Multicenter Pragmatic Non-Inferiority Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07769008
Status Recruiting
Phase
Sponsor Ruijin Hospital
Condition Coronary Artery Disease
Study Type INTERVENTIONAL
Enrollment 826 participants
Start Date 2026-08-17
Primary Completion 2029-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
CCTA-based CABGCAG-based CABG

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 826 participants in total. It began in 2026-08-17 with a primary completion date of 2029-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to find out if using a non-invasive heart scan (called coronary computed tomography angiography, or CCTA) to plan coronary artery bypass grafting (CABG) works as well as the standard invasive approach (called coronary angiography, or CAG) for people with blocked heart arteries. The main questions it aims to answer are: Do people who have surgery planned with the non-invasive heart scan have similar health outcomes at 1 year as those who have surgery planned with the standard invasive approach? How does the non-invasive approach compare in terms of heart attacks, strokes, unplanned repeat procedures, and longer hospital stays? Researchers will compare two groups of participants. One group will have their surgery planned using only the CCTA . The other group will have their surgery planned using only the CAG. Both groups will undergo the CABG per local protocol. Participants will: Be randomly assigned (like flipping a coin) to one of the two planning approaches Undergo CABG as scheduled Return for follow-up visits at sugery days, 7 days, 1 month, 6 months, and 1 year after surgery Have a follow-up CCTA scan at 7 days and 1 year to check if the new bypass grafts are working well

Eligibility Criteria

Inclusion Criteria: * Referred to CABG treatment Exclusion Criteria: * Under the age of 18 years * Unable to provide informed consent * Emergency CABG * Redo-CABG * Prior PCI with coronary stent implantation * Cardiogenic shock * Unable to undergo CAG or CCTA examination or deemed unsuitable by the investigator, such as: Known allergy to iodinated contrast media; Active hyperthyroidism or uncontrolled thyroid disease; Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m²; Atrial fibrillation with rapid ventricular response or severe arrhythmias not amenable to rate control; * Pregnancy, lactation, or childbearing potential without effective contraception in female participants * Concurrent participation in another interventional trial

Contact & Investigator

Central Contact

Yunpeng Zhu, MD

✉ zyp12220@rjh.com.cn

📞 0086-02164370045

Frequently Asked Questions

Who can join the NCT07769008 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07769008 currently recruiting?

Yes, NCT07769008 is actively recruiting participants. Contact the research team at zyp12220@rjh.com.cn for enrollment information.

Where is the NCT07769008 trial being conducted?

This trial is being conducted at Shanghai, China.

Who is sponsoring the NCT07769008 clinical trial?

NCT07769008 is sponsored by Ruijin Hospital. The trial plans to enroll 826 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology